C1orf50 and breast carcinoma: Using the median of C1orf50 mRNA expression values, we divided stage II breast cancer patients into C1orf50-high and C1orf50-low groups and performed survival analysis of stage II breast cancer patients, finding a significant (p = 0.045) difference in 10-year survival (Fig. 1C).